Literature DB >> 26443611

Influence of Sex on Long-Term Outcomes After Implantation of Bare-Metal Stent: A Multicenter Report From the Coronary Revascularization Demonstrating Outcome Study-Kyoto (CREDO-Kyoto) Registry Cohort-1.

Kyohei Yamaji1, Hiroki Shiomi1, Takeshi Morimoto1, Toshiaki Toyota1, Koh Ono1, Yutaka Furukawa1, Yoshihisa Nakagawa1, Kazushige Kadota1, Kenji Ando1, Shinichi Shirai1, Masayuki Kato1, Yoshiki Takatsu1, Osamu Doi1, Hirofumi Kambara1, Satoru Suwa1, Tomoya Onodera1, Hirotoshi Watanabe1, Masahiro Natsuaki1, Takeshi Kimura2.   

Abstract

BACKGROUND: Female sex was reported to be associated with lower risk for midterm restenosis and repeat revascularization after bare-metal stent implantation. However, the influence of sex on very long-term outcomes after bare-metal stent implantation has not been yet reported. METHODS AND
RESULTS: Among the 9877 patients in the multicenter Coronary Revascularization Demonstrating Outcome study in Kyoto (CREDO-Kyoto) registry cohort-1, bare-metal stent implantation was performed in 5313 patients (men, n=3742 and women, n=1571). Follow-up was completed in 4515 patients (85.0%) at 10 years (duration, 10.3 ± 3.1 [0.0-14.1] years). The cumulative incidence of target-lesion revascularization (TLR) was 27% at 1 year and 34% at 10 years (0.8%/y beyond 1 year). Non-target-lesion revascularization (non-TLR) was the dominant coronary revascularization beyond 1 year (13% at 1 year and 31% at 10 years [2.0%/y beyond 1 year]). Cumulative incidence of stent thrombosis was low (1.2% at 1 year and 1.9% at 10 years). Women were older and had greater prevalence of cardiovascular risk factors than men. The cumulative 10-year incidences of and adjusted risk for TLR were significantly higher in men than in women (36% versus 30%, P<0.001; adjusted hazard ratio, 1.29; 95% confidence interval, 1.15-1.46; P<0.001). The higher risk of men relative to women for TLR was consistent regardless of age (<75 years and ≥ 75 years). Men in comparison with women were also associated with significantly higher adjusted risks for all-cause death, myocardial infarction, stroke, coronary artery bypass grafting, TLR, and non-TLR.
CONCLUSIONS: TLR and stent thrombosis continued to occur without attenuation up to 10 years after bare-metal stent implantation. Men in comparison with women were associated with higher adjusted 10-year risks for all-cause death, myocardial infarction, stroke, coronary artery bypass grafting, TLR, and non-TLR.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  coronary artery disease; coronary restenosis; sex; stents

Mesh:

Substances:

Year:  2015        PMID: 26443611     DOI: 10.1161/CIRCULATIONAHA.115.017168

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

Review 1.  GPER-novel membrane oestrogen receptor.

Authors:  Margaret A Zimmerman; Rebecca A Budish; Shreya Kashyap; Sarah H Lindsey
Journal:  Clin Sci (Lond)       Date:  2016-06-01       Impact factor: 6.124

2.  <Editors' Choice> Very long-term clinical outcomes after percutaneous coronary intervention for complex vs non-complex lesions: 10-year outcomes following sirolimus-eluting stent implantation.

Authors:  Shuro Riku; Susumu Suzuki; Tsuyoshi Yokoi; Teruhiro Sakaguchi; Toshihiko Yamamoto; Yasushi Jinno; Akihito Tanaka; Hideki Ishii; Yasuya Inden; Toyoaki Murohara
Journal:  Nagoya J Med Sci       Date:  2022-05       Impact factor: 0.794

3.  Sex differences in arterial identity correlate with neointimal hyperplasia after balloon injury.

Authors:  Mingjie Gao; Xixiang Gao; Ryosuke Taniguchi; Anand Brahmandam; Yutaka Matsubara; Jia Liu; Hao Liu; Weichang Zhang; Alan Dardik
Journal:  Mol Biol Rep       Date:  2022-06-17       Impact factor: 2.742

4.  Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy.

Authors:  Gábor Csató; Nóra Erdei; Beatrix Ványai; Tímea Balla; Dániel Czuriga; Zoltán Csanádi; Zsolt Koszegi; István Édes; Gábor Tamás Szabó
Journal:  Front Cardiovasc Med       Date:  2022-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.